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Background: Thoracic endovascular aortic repair of aortobronchial fistulas is an emerging treatment modality for this
highly lethal condition. The feasibility and long-term durability of this form of intervention are largely unknown.
Methods: The records of five patients who received endografts to treat aortobronchial fistulas at our institution were
reviewed. A literature review was also conducted using MEDLINE to identify reports detailing outcomes of patients
undergoing thoracic endovascular aortic repair for this condition. Primary outcome end points included intraoperative
mortality, 30-day mortality, and aortobronchial fistula recurrence.
Results: For the five patients treated at our institution, technical success was 100%. In follow-up, aortobronchial fistulas
recurred in two patients, resulting in one patient death and one endograft explantation. We identified 32 reports that met
inclusion for our final review. Inclusive of the five patients treated at out institution, 67 patients with reported outcomes
comprised the overall analysis. Most patients (55%) had previously undergone thoracic aortic surgery. Commercially
manufactured thoracic endografts were used in 75% of patients. No intraoperative mortality was reported, and the 30-day
mortality was 1.5%. Aortobronchial fistula recurred after endovascular repair in six patients (9%) through a mean
follow-up of 21.5 months. Three cases of recurrent aortobronchial fistula resulted in patient death.
Conclusions: Thoracic endovascular aortic repair of aortobronchial fistulas appears to a viable alternative to conventional
open repair with excellent short-term results. Recurrence of the aortobronchial fistula after endovascular repair is a
potential complication necessitating long-term surveillance. Individual risk assessment is needed to determine if
endovascular repair should be used as bridge therapy or as a definitive repair. ( J Vasc Surg 2009;50:992-8.)Aortobronchial fistula (ABF) is a rare, life-threatening
condition that represents a communication between the
thoracic aorta and the tracheobronchial airway. This con-
dition often occurs in the setting of an atherosclerotic
aneurysm or pseudoaneurysm after thoracic aortic surgery.1
ABFs are highly lethal if they are not diagnosed and remain
untreated.1-3 A definitive diagnosis, however, can some-
times be difficult, but an ABF should be highly suspected in
patients with a history of known or previously treated
thoracic aortic pathology.
Conventional open surgical intervention for ABFs is
associated with substantial morbidity and mortality.1,3 The
high complication rate can be attributed to the need for an
emergency intervention in patients with multiple pre-existing
comorbidities through what will often be a reoperative
surgical approach. Recent advances in endovascular tech-
nology have allowed for endoluminal repair of multiple
aortic pathologies, with the potential for improved out-
comes compared with traditional interventions. For ABFs,
thoracic endovascular aortic repair (TEVAR) affords the
ability to rapidly obtain hemorrhage control while avoiding
the inherent morbidity associated with thoracic aortic ex-
posure and aortic cross-clamping.
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992Experience with endovascular repair of ABFs is greatly
limited by the rarity of this condition and the relatively
recent evolution of TEVAR procedures. Reported out-
comes after TEVAR for ABFs have been largely limited to
individual case reports4-16 or small case series.17-24 To
evaluate the feasibility of TEVAR for ABFs, we reviewed
our single-institution case series and initiated an extensive
review of the published experience to date.
METHODS
Institutional Review Board approval was obtained for
the review of all patient records relevant to this study. A
search was conducted of our institutional TEVARDatabase
from March 1998 to September 2007. During this time
period, 195 patients received endografts for multiple tho-
racic aortic pathologies, and five (2.6%) underwent emer-
gency TEVAR for ABFs. A full review of radiographic,
electronic, and paper records was performed. Anatomic
requirements, sizing of endografts, and follow-up were as
previously described.25
A search of the MEDLINE database was conducted
from January 1990 to January 2008 through PUBMED
using the keywords aortobronchial, aorto-bronchial, aorto-
pulmonary, aorto-pulmonary, aortotracheal, and aortobron-
chopulmonary. The search was limited to English-language
literature and the treatment of adult patients (aged 18
years). Abstracts were screened for articles describing at
least one patient undergoing TEVAR for an ABF. Refer-
ences in the identified articles were further screened for
additional publications not identified in the initial database
search. Articles were selected for further review and inclu-
sion in the final analysis if they described individual out-
comes for patients treated for ABFs. Patients reported as
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typically excluded because these studies often only reported
summarized outcome data of the endovascular treatment
of multiple thoracic aortic pathologies. Multiple publica-
tions originating from a single institution describing the
same patients were identified and the older publications
were excluded.
Data points of interest included age, gender, associated
thoracic aortic pathology, diagnostic procedures performed
before TEVAR, endografts used, intraoperative mortality,
30-day mortality, and ABF recurrence. The number and
percent reporting for each respective data point is presented
when 100% of the data points were obtained from the
total number of identified patients. Mean values that were
reported for data points of interest in individual ABF case
series20,21 were weighted against the number of reported
patients in the respective report for the final calculations.
RESULTS
Characteristics of the five patients from our institu-
tional series are compiled in Table I. Three patients pre-
sented with pseudoaneurysms associated with prior surgery
of the thoracic aorta. An additional patient, who had un-
dergone anterior spinal fixation for complications from
multiple myeloma, presented with a small pseudoaneurysm
at the level of his spinal hardware. Computed tomography
(CT) angiography findings, laboratory studies, and physical
examination findings were not suggestive of an infectious
cause. The patient was assessed as most likely having sus-
tained an iatrogenic thoracic aortic injury at the time of his
spinal procedure. The final patient presented with a primary
mycotic aneurysm.
CT was performed in four patients who presented to
the hospital with a history of recurrent hemoptysis. Aortog-
raphy was use to evaluate the fifth patient who presented
with a primary mycotic thoracic aortic aneurysm after an
acute episode of hemoptysis shortly after admission. Al-
though all studies demonstrated associated thoracic aortic
pathology, none directly demonstrated a fistula. Bronchos-
copy was performed in two patients, without identification
of a fistulous orifice.
Because the study period spanned the era before and
Table I. Patient characteristics





1 53 M PA/mycotic S aureus DTA repair (0.7 y)
2 77 M PA ... Ao-L SCA bypass
(35 y)
3 52 M PA ...
4 71 M PA ... DTA repair (7 y)
5 71 F Mycotic S aureus
Ao-L SCA, Aorta to left subclavian artery; DTA, descending thoracic aneu-
rysm; PA, pseudoaneurysm.
aYears before endovascular intervention in parentheses.after thoracic endograft approval in the United States,the devices used included approved thoracic devices,
compassionate-use thoracic devices, and modified abdom-
inal endograft components (Table II). Technical success
was 100% as assessed by intraoperative angiography and
postoperative CT scans.
Patient outcomes are presented in Table II. Two
patients experienced prolonged hospital stays (7 days)
after endovascular repair. In one of these patients, who
presented with a pseudoaneurysm at the proximal anas-
tomotic site of an aorta to left subclavian bypass, multiple
pneumonias developed as well as a cerebrovascular acci-
dent 2 weeks after his intervention. After discharge to an
acute care facility, he made a complete functional recov-
ery. Life-long prophylactic antibiotics were recom-
mended due to the potential for endograft contamina-
tion from the multiple infections the patient experienced
during his hospital stay. CT scans at 6 months and 1 year
demonstrated progressive resolution of his periaortic
hematoma (Fig). In the second patient, who presented
with a primary mycotic aneurysm, the hospital stay was
prolonged due to multiple fungal and bacterial pneumo-
nias. This patient was discharged to an acute care facility
and died 5 months after TEVAR from complications of
pre-existing end-stage renal disease.
Two patients experienced recurrent episodes of he-
moptysis 48 hours after TEVAR. In both patients, CT
angiography evaluation demonstrated no evidence of en-
doleak and bronchoscopy demonstrated no evidence of
active bleeding. These episodes resolved and were attributed
to expectoration of residual clots in the airways because there
was no significant change in the patients’ hemoglobin or other
signs of a persistent fistulous connection.
Two patients (40%) experienced an ABF recurrence
during follow-up. In one patient, hemoptysis developed 11
months after TEVAR during hospitalization for acute pan-
creatitis. CT angiography revealed periaortic inflammation
at the level of the endograft. The patient refused interven-
tion, despite being amenable to further endovascular repair,
and died after a massive hemoptysis.
The second patient, who had developed a pseudoaneu-
rysm after spinal surgery, presented 33 months after
TEVAR with recurrent hemoptysis, Pseudomonas bactere-
mia, and pneumonia. The patient had previously experi-
enced multiple admissions at another hospital for various
infections. CT angiography at the time of presentation
demonstrated proximal aortic aneurysmal enlargement and
periaortic inflammation. The patient’s immune dysfunction
from myeloma may have been a contributing factor in the
development of an endograft infection. The patient under-
went endograft explantation through a two-stage proce-
dure. During the initial stage, an ascending to descending
thoracic aortic bypass was performed through a median
sternotomy. After partial recovery, the patient underwent
thoracic aortic resection and wedge resection of the left
upper lobe through a left thoracotomy. The patient made a
full recovery without complications. Imaging at 6 months
demonstrated no anastomotic concerns and resolution of
the residual pulmonary inflammation.
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case series, of which eight were excluded from the final
analysis due to reports on the same patients in prior publi-
cations. Included were 11 publications that reported pa-
tients with ABF along with other thoracic aortic patholo-
gies.26-36 The 32 reports used in the final analysis are
presented in Table III. Inclusive of the five patients de-
scribed from our institutional series, data from 67 patients
were available for the overall analysis.
Of the 64 patients for whom age and gender were
reported, the mean age was 64.3 years and 69% were men.
Most reported cases (55%) occurred in patients who had
previously undergone thoracic aortic surgery, and of these
36 patients, 14 (39%) had undergone the initial aortic
operation for aneurysms or pseudoaneurysm of the de-
scending thoracic aorta and 13 (36%) for congenital aortic
coarctation. Accounting for reoperative aortic procedures,
the mean time from the most recent aortic surgery to
TEVAR for the 26 patients reported was 13.2 years.
Most patients (75%) received commercially manufac-
tured thoracic endografts (Table IV). Hand-made devices
comprised approximately 14%, although these predomi-
nantly occurred in earlier reports or from countries with
limited endograft availability. A mean of 1.3 components
were deployed per patient. Nine secondary endovascular
procedures were performed in eight patients, and seven of
these were performed30 days from the initial procedure.
Seven procedures (78%) were performed because of a doc-
umented endoleak.
Early postoperative recurrent hemoptysis was reported
in eight patients (12%), although in seven the hemoptysis
resolved without intervention. Hemoptysis recurred 48
hours after TEVAR in one patient. This was found to be
due to an endoleak with persistence of the ABF7 and was
successfully treated with deployment of an additional com-
ponent.
Length of stay averaged 11.5 days (range, 1-57 days),
but this was only reported in 38 patients (57%). No intra-
operative deaths were reported. The only death (1.5%) that
occurred 30 days was in a patient with pneumonia who
refused intubation.6 The ABF recurred in six patients (9%)
at a mean of 13.2 months after TEVAR (range, 2 days-33
Table II. Patient outcomes
Patient Endograft No.a Length of stay, d Antibiotics at dis
1 Zenithb 1 7 Yes
2 Zenithb 3 50 Yes
3 TAGc 1 1 No
4 TAGc 1 6 No
5 Talentd 2 64 Yes
ABF, Aortobronchial fistula.
aNumber of endograft components deployed.
bZenith AAA endovascular graft (Cook, Bloomington, Ind).
cW. L. Gore & Associates, Flagstaff, Ariz.
dMedtronic AVE, Santa Rose, Calif.months). Three cases of recurrence were successfullytreated with additional operative or endovascular interven-
tions, and three cases resulted in patient death.
DISCUSSION
ABF is a rarely encountered clinical entity. A literature
review published in 1991 identified 63 reported cases.1 An
additional review of postoperative ABFs revealed only 76
patients reported through 2002.3 When left untreated, this
condition is invariably fatal, with reported mortality rates of
100%.1-3
Patients who develop ABFs often present with hemop-
tysis that is mild and intermittent in nature for which the
etiologic differential is diverse. The ability to diagnose this
condition is further confounded by the lack of a diagnostic
test that can clearly demonstrate the presence of the fistula.
Although helical CT imaging will rarely demonstrate a
fistulous communication between the aorta and the lung,
thoracic aortic pathology with adjacent lung parenchymal
changes are highly suggestive of the diagnosis in this clinical
setting.37 Aortography and bronchoscopy are often part of
the evaluation of hemoptysis; however, both of these mo-
dalities often fail to demonstrate the fistula2 and may po-
tentially induce massive hemorrhage.3
Traditional operative intervention consists of closure of
the aortic defect with anatomic reconstruction, débride-
ment and drainage, or possibly extra-anatomic bypass and
resection. This treatment affords the ability to directly
address both the aortic and bronchopulmonary defects as
well as perform surgical débridement of infected tissues in
cases of a mycotic aneurysm. Open surgical repair has been
reported to carry an operative mortality rate of 15.3% to
24%.1,3,38 Much of this mortality may largely be due to the
need to perform reoperative thoracic exposures in patients
who have previously undergone thoracic aortic surgery.1,3
In a review of the literature, Piciche et al3 reported a 16%
operative mortality for patients undergoing open repair of
postoperative ABFs, with six of these eight deaths occur-
ring intraoperatively.3 The results from this review of
TEVAR of ABFs compare favorably with these historic
outcomes, as we could find no reports of intraoperative
death and only one hospital death (1.5%) at 30 days in a
e Length of follow-up, mon Recurrent ABF Mortality (mon)




5 No Yes (5 mon)chargpatient who refused intervention for pneumonia.6
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the leading cause of ABFs, but this condition now most
commonly presents in the setting of atherosclerotic an-
eurysms or pseudoaneurysms associated with prior tho-
racic aortic surgery.1 Experience with using endografts in
patients with mycotic aneurysms is limited, and unlike
open surgery, TEVAR does not afford the opportunity to
perform débridement of the infected aorta and sur-
rounding tissues. Whether the local infection can be
completely resolved when an endoprosthesis is placed
within the infected field is unknown. A recent review of
the endovascular treatment of mycotic aneurysms sug-
gests that this condition may be successfully managed
with endografts; however, patients with ruptured aneu-
rysms, which included patients with ABFs, were more
likely to have a persistent infection.39
Our two cases of recurrent ABFs were both related to
infection. One ABF recurred at 11 months, despite main-
tenance antibiotic therapy, in a patient who was infected at
the time of TEVAR. The other ABF occurred secondary to
a late endograft infection, potentially as a consequence of
the patient’s immune dysfunction. In situations of an asso-
ciated graft infection or mycotic aneurysm, it may be more
appropriate to use endografts to temporarily achieve hem-
orrhage control and serve as a bridge to an open surgical
intervention. The plan of treatment should be individual-
ized for each patient according to his or her risk factors at
the time of presentation.
The appropriate duration of postoperative antibiotics
in the presence or absence of documented infection in the
setting of ABFs is undefined. Although ABFs may often
develop in the absence of an infectious etiology, the lack of
closure of the pulmonary defect after TEVAR may expose
the endoprosthesis to a contaminated environment. Whether
this may increase the patient’s risk for the development of
an endograft infection is unknown. Our current practice is
to prescribe life-long antibiotic therapy for patients after
TEVAR for infectious aortic pathology. In the absence of
an infectious aortic etiology and an uncomplicated postop-
erative course, the patient will not be discharged on antibi-
otics.
Recurrent hemoptysis after TEVAR was commonly
reported in the postoperative period, with an incidence
of 12%. Many of these cases prompted a diagnostic
evaluation owing to concern for persistence of the ABF,
but in only one patient was the hemoptysis attributed to
the presence of an endoleak with a persistent communi-
cation between the aneurysm sac and the bronchopul-
monary system. These cases of early postoperative he-
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig. Computed tomography angiography of the chest (A) before
(B) 6 months, and (C) 12 months after endovascular repair in a
patientwhopresentedwithmassive hemoptysis andwas found tohave
a pseudoaneurysm (arrow) at the proximal aspect of an aorta to left
subclavian artery bypass. Exclusion of the aneurysm and progressive
resolution of the associated hematoma is demonstrated.
JOURNAL OF VASCULAR SURGERY
November 2009996 Riesenman et almoptysis resolution without intervention are most likely
the result of resorption and expectoration of the residual
mediastinal hematoma after exclusion of the fistula, as
suggested by Dorweiler et al.28 Resolution of postinter-
vention hemoptysis secondary to hematoma expectora-
tion may be protracted and has been reported to persist
for as long as 2 weeks.28 Given the potential for recurrent
ABF from inadequate exclusion from the aortic circula-
tion or retrograde perfusion of the aneurysm sac from
intercostal or bronchial vessels, diagnostic evaluation
should be conducted if clinically warranted.
The durability of TEVAR for the treatment of ABF is
partially assessed by the recurrence of this condition. Our
literature review found a reported recurrence rate of 9.0%,
presenting at a mean of 13.2 months from the time of
intervention. Other then the one case that occurred at 2
days after TEVAR, the remaining cases all presented at 6
months. These late failures may be the result of primary or
secondary aortic infection, as illustrated by our two patients
Table III. Published case reports and case series of thorac
First author Year Patients, No.
Mortalit
Intra-op
Chuter4 1996 1 0 (0)
Campagna5 1996 1 0 (0)
Semba26 1998 1 0 (0)
Miyata17 1999 2 0 (0)
Karmy-Jones6 1999 1 0 (0)
Caiati7 2001 1 0 (0)
Kramer27 2001 1 0 (0)
Yoo8 2001 1 0 (0)
Dorweiler28 2001 3 0 (0)
Leobon29 2002 3 0 (0)
Schoder30 2002 3 0 (0)
Alric31 2002 1 0 (0)
Bockler18 2004 8 0 (0)
Kotzampassakis9 2004 1 0 (0)
Numan10 2004 1 0 (0)
Saratzis11 2005 1 0 (0)
Munneke12 2005 1 0 (0)
Jones32 2005 1 0 (0)
Kaw113 2005 1 0 (0)
Beland14 2005 1 0 (0)
Sayed24 2005 3 0 (0)
Abdul-Ghani115 2006 1 0 (0)
Kaya33 2006 2 0 (0)
Matsagas34 2006 1 0 (0)
Kwok35 2006 1 0 (0)
Takahashi119 2006 2 0 (0)
Quintana16 2006 1 0 (0)
Pirrelli20 2006 5 0 (0)
Wheatley21 2007 7 0 (0)
Kokotsakis22 2007 2 0 (0)
Sachithanandan23 2007 2 0 (0)
Marcheix36 2007 1 0 (0)
Present series 2008 5 0 (0)
Overall 67 0 (0)
ABF, Aortobronchial fistula; NR, not reported.
aFollow-up reported on one patient in the case series.
bFollow-up reported for 60 of 67 patients.with ABF recurrence, or as a result of progression of theassociated thoracic aortic pathology present at the time of
TEVAR. This potential for recurrence, and other late en-
dograft complications, necessitates life-long imaging sur-
veillance as performed for other thoracic aortic pathologies
after endovascular repair.
One limitation of this review is that the cases summa-
rized may represent a bias toward good outcomes because
clinicians may be unlikely to publish unfavorable results
after endovascular management of this condition. In addi-
tion, follow-up was limited in several of the case reports and
case series. Therefore, the true procedurally related mortal-
ity may not be reflected within the first 30 days, although
mortality beyond this time frame is probably more a func-
tion of the inherent insult of this condition and associated
comorbidities in this patient population.
Although early outcomes from this review appear to be
favorable compared with reviews of the literature reporting
outcomes of open surgical intervention, the results from
these studies mainly reflect historical open surgical out-
dovascular aortic repair of aortobronchial fistulas
. (%)
Recurrent ABF, No. (%) Mean follow-up, mon30-day
(0) 0 (0) 7
(0) 0 (0) 36
(0) 0 (0) 25
(0) 0 (0) 8a
(100) 0 (0) 0.7
(0) 1 (100) 2
(0) 0 (0) 12
(0) 0 (0) 0.5
(0) 0 (0) 35.3
(0) 0 (0) 19.3
(0) 1 (33) 23a
(0) 0 (0) NR
(0) 1 (13) 28.5
(0) 0 (0) 0.5
(0) 0 (0) 6
(0) 0 (0) 7
(0) 0 (0) 12
(0) 0 (0) 28
(0) 0 (0) 2
(0) 0 (0) 12
(0) 1 (33) 16.7
(0) 0 (0) 9
(0) 0 (0) NR
(0) 0 (0) 18
(0) 0 (0) NR
(0) 0 (0) 18
(0) 0 (0) 12
(0) 0 (0) 26.4
(0) 0 (0) 42.6
(0) 0 (0) 31.5
(0) 0 (0) 9
(0) 0 (0) 12.9
(0) 2 (40) 13.8



































1comes from the pre-endovascular era.1,3 Outcomes re-
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results that could presently be obtained due to modern
advancements in the field of cardiovascular surgery.
Conversely though, many of the patients who under-
went TEVAR in this overall series might have been prohib-
itive candidates for open surgery and might not have been
offered an intervention in the absence of an endovascular
option. Direct comparisons between open surgical and
endovascular interventions are impractical because of the
emergency nature of this condition and the rarity with
which it is encountered. Continued evaluation of the feasi-
bility of TEVAR for the treatment of ABFs will largely
continue to come from the clinical experience obtained
from the endovascular treatment of other thoracic aortic
conditions.
CONCLUSIONS
TEVAR is a promising intervention for the treatment of
ABFs, with minimal procedurally related mortality. Whether
this intervention represents a definitive form of repair or a
temporizing measure to obtain hemorrhage control for
some associated thoracic aortic conditions remains to be
defined. Although early postintervention hemoptysis is
common and most likely due to expectoration of hema-
toma, evaluation for failure of exclusion should be per-
formed if clinically warranted. In addition, the ABF may
recur after an initially successful TEVAR procedure, neces-
sitating continued clinical and radiographic surveillance.
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